Filed Under: Biologics, Dermatology, Immunology, Infectious Disease, Metabolic disease/endicrinology, Oncology Tagged With: AbbVie, biologic drugs, biosimilar competition, drug sales H1 2025, Eli Lilly, GLP-1 drugs, IL-23 inhibitors, immunology drugs, Keytruda patent expiry, loss of exclusivity, Merck, Novo Nordisk, obesity drugs, Oncology Therapeutics, patent cliff 2028, PD-1 inhibitors, pharmaceutical blockbusters, prescription drug market, Skyrizi, therapeutic categories Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
It remains to be shown whether ROXY9 controls TGA1 activity through a direct redox mechanism or whether the highly solvent-exposed CCLC signature is important for redox-independent protein-protein interactions within regulatory complexes
Your energy is flat, your body composition has barely shifted, and your mood is inconsistent in ways you can't quite explain
Sometimes alternative medications are available, though you should never stop taking prescribed medications without medical guidance
Diabetes medications: insulin, pioglitazone (Actos), glipizide (Glucotrol), etc
Phytother Res 27(10):15361542 Baralic I et al (2015) Effect of astaxanthin supplementation on salivary IgA, oxidative stress, and inflammation in young soccer players
